A Phase 4 interventional study of Methadone and Placebo in Post Operative Pain and Spinal Surgery, sponsored by The Cleveland Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 72 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-17.
Sponsored by The Cleveland Clinic · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies testing methadone in Pain, Postoperative — 8 open to participants now, 8 under way, 3 of them phase 3. Methadone · Pain, Postoperative.
Among the 37 studies testing methadone in Pain, Postoperative, this one is the 10th largest by planned enrollment, is one of 2 that started in 2025, is one of 21 in phase 4, and was the 32nd registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →8 of the 37 studies testing methadone in Pain, Postoperative are open now, in 2 countries. Recruiting first, the newest first:
Brandon Knopp · Sites in United States
Ages 18–120
Medical University of South Carolina · Sites in United States
Ages 18–75
Medical University of South Carolina · Sites in United States
Ages 18–75
Duke University · Sites in United States
Ages 3–17 · Healthy volunteers
University of Virginia · Sites in United States
Ages 18–75
By country, each count listing its studies:
Methadone: first FDA approval 1947 (DOLOPHINE HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years to 72 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 7 · Phase 4 21
First in 2009; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 75 across the 37 interventional studies. Of the 25 that completed or were terminated, 10 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 37 has an industry lead sponsor. The 10 most frequent:
The Cleveland Clinic is the lead sponsor of 832 studies on the registry; 119 are open to participants now.
Of its 90 completed or terminated interventional studies of FDA-regulated products, 73 (81%) have results posted.
24 studies in Pain, Postoperative by The Cleveland Clinic: 2 open now, 3 under way, 1 of them phase 3. Of 18 finished, 12 (67%) have results posted.
Among the 24 studies in Pain, Postoperative by The Cleveland Clinic, this one is the 11th largest by planned enrollment of the 23 interventional ones that give a count, is the only one that started in 2025, is one of 9 in phase 4, and was the 24th registered.
The Cleveland Clinic’s Pain, Postoperative studies by the year they started, since 2003.
5 of the studies testing methadone in Pain, Postoperative that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07226076Phase 3Medical University of South CarolinaMethadone in TKA for Post-op Pain and Opioid Reduction | 2026-12-28 |
| NCT07565870Phase 3Alexandre P. JoostenMethadone for Enhanced Postoperative Analgesia in Intermediate-Risk Noncardiac Surgery (MELODY) | 2026-12-31 |
| NCT07227064Phase 3Medical University of South CarolinaMethadone in THA for Post-op Pain and Opioid Reduction | 2026-12-31 |
| NCT07517679Brandon KnoppMethadone for Post-operative Spine Surgery | 2027-04 |
| NCT07222072The Cleveland ClinicMethadone to Reduce Chronic Opioid Use After Major Spine Surgery: The MEND Pilot Feasibility Study | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 37 studies testing methadone in Pain, Postoperative, from their registry updates:
Among The Cleveland Clinic’s 24 in Pain, Postoperative:
This tab as a report to print or save as PDF → With an account.
The investigators propose a randomized, triple-blinded (patients, investigators, outcomes assessors), placebo-controlled pilot feasibility trial (Methadone to End Narcotic Dependence, MEND trial) to assess the feasibility and safety of postoperative oral methadone in patients undergoing spine surgery and collect preliminary data to inform a larger clinical trial that will test the opioid-sparing effects of methadone at 3 months after spine surgery.
The Centers for Disease Control and Prevention reports a nearly 10-fold increase in the number of deaths from all types of drug overdose over the past 20 years, including 82,000 deaths that occurred in 2022 alone. Prescription opioid medications contribute to drug overdose deaths. In fact, nearly 294,000 people in the US died from a drug overdose involving prescription opioid medications between 1999 and 2022 - a 4-fold increase in prescription drug overdose deaths. Surgery is often the first exposure to opioid medications for many patients. Severe pain after surgery requires potent opioid medications which control pain but includes risk of long-term opioid-dependence. Long-term opioid use and abuse may lead to opioid addiction, overdose and even death.
Patients undergoing spine surgery experience severe postoperative back pain immediately after surgery, which requires treatment with potent opioid medications. Severe pain in the first 1 to 3 days after surgery often develops into chronic back pain, which increases risk for long-term use and abuse of prescription opioid drugs. Importantly, compared with all other surgical procedures, back and spine surgery is associated with the highest risk of long-term use and abuse of prescription opioid medications. Certainly, chronic back pain requires opioid use in approximately 50% of patients at three months after surgery, 40% at six months, 30% at one year, and 17% at two years. A financial burden exists as well. Over the past 10 years, annual prescription opioid expenditures for pain after spine-related surgery increased 660% from $246 million in 1997 to $1.9 billion in 2006. Monthly direct and indirect costs associated with the treatment of postoperative persistent and chronic back pain totaled an average US $3,455 per patient. These data indicate that new approaches that provide effective, long-lasting, and safe treatment of postoperative pain after complex spine surgery while reducing risk of persistent and chronic postoperative pain and prolonged opioid use and reducing cost are needed.
Multiple randomized clinical trials in patients undergoing a variety of surgical procedures have demonstrated that intraoperative methadone significantly reduces postoperative analgesic requirements in the immediate postoperative period, compared to shorter-acting opioids. Methadone is a unique long-acting opioid medication that demonstrates rapid onset and prolonged duration of action with a half-life of 24-36 hours and pain relief lasting 8-12 hours. Like other opioids, methadone activates the mu-opioid receptor, but it also has additional effects on the brain, such as blocking NMDA receptors and reducing reuptake of serotonin and norepinephrine. These actions may help improve recovery by reducing pain sensitivity, preventing tolerance to the medication with euphoric effects, preventing opioid-induced hyperalgesia and opioid tolerance. One investigation studied the impact of methadone on persistent and chronic post-surgical pain in a small randomized controlled trial (RCT) with 66 patients. Participants were randomized to receive either a single intraoperative intravenous dose of methadone (0.2 mg/kg) or intravenous hydromorphone (2 mg). Methadone not only reduced the incidence of post-surgical pain in the study group. but also the percentage of patients who required opioid analgesics at three months (10 versus 41%), suggesting a protective effect against prolonged opioid consumption. Pilot data from another investigation using preoperative oral methadone in patients undergoing cardiac surgery showed reduction in postoperative morphine consumption in the first 24 hours. If acute postoperative pain is reduced, the development of chronic pain may also decrease, as well as the need for long-term opioid therapy, dependence, and abuse.
Although methadone provides effective analgesia for major surgery, a thorough safety assessment of perioperative intravenous methadone is needed. A large retrospective study of 1,478 patients after major spine fusion surgery who received IV methadone (0.13 mg/kg) along with other analgesics, including lidocaine, ketamine, and hydromorphone noted respiratory depression in one-third of patients and hypoxia in nearly 80%. Other concerns include a nearly 60% incidence of electrocardiographic QTc prolongation and 1.1% experienced myocardial infarction (MI) postoperatively. However, there is limited data on the impact of a single perioperative dose of methadone on QTc prolongation. Additional potential complications such as respiratory depression requires further investigation.
If proven safe and effective, postoperative pain therapy with methadone could offer a simple, practical strategy to improve long-term outcomes in this high-risk population undergoing spine surgery. This investigation will the safety and efficacy of postoperative methadone treatment in patients undergoing spine surgery and the opioid-sparing effects of methadone at 3 months after surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to receive post operative methadone
Drug: Methadone
Patients will receive post operative placebo
Drug: Placebo
Patients randomized to receive (blinded) methadone: 5 mg twice daily on postoperative (post-op) days 1 and 2 followed by 5 mg daily on postop days 3, 4, and 5.
Also known as: Methadone (Blinded) Group
Patients randomized to receive (blinded) placebo will receive placebo twice daily on day 1 and day 2 and once daily on day 3, 4 and 5. Patients taking preoperative opioids will return to baseline opioid schedule after surgery.
Also known as: Placebo (Blinded) Group
Feasibility and Acceptability-Participant Willingness/Recruitment
Willingness of participants to be randomized Indicates acceptability of randomization among eligible patients Outcome Measure: % of eligible patient consenting to randomization
Time frame: 7 days
Feasibility and Acceptability-Provider Engagement
Feasibility, acceptability and execution of clinical protocol based on the use of intraoperative IV methadone followed by a postoperative oral methadone regimen following spine surgery will be assessed by yes/no response to the following: Willingness of neurosurgeons/anesthesiologists to buy in to the trial Reflects institutional buy-in and clinical integration potential Outcome Measure: % of surgeons permitting patient enrollment and supporting protocol adherence
Time frame: 7 days
Feasibility and Execution-Protocol Compliance and Execution
Feasibility of clinical protocol based on the use of intraoperative IV methadone followed by a postoperative oral methadone regimen following spine surgery will be assessed by yes/no response to the following: Compliance with the protocol, including specific study related procedures and timepoints specific to medication administration, adverse event reporting and data collection. Demonstrates deliverability and data reliability Outcome Measure: % adherence to all major protocol steps (drug administration, ECGs, AE reporting, opioid data)
Time frame: 7 days
Acceptability and Execution-Baseline Stratification Data
Outcome Measure: % of enrolled patients with prior chronic opioid use
Time frame: 18 months
Feasibility and Execution-Follow-Up Completion
Ability to assess primary endpoint (opioid use at 3 months).Measured by response rates to the telephone survey at 3 months
Time frame: 90 days
Execution-Collection of Cardiac Rhythm Abnormalities
1\) ECG collected on postoperative days 1, 2 and 3. Presence of cardiac arrhythmias (frequent premature ventricular contractions, ventricular arrhythmias) requiring treatment will be collected. An increase in QTc interval \>500 ms or \>25% from baseline will be compared to baseline ECG,
Time frame: 18 months
Execution-Collection of Respiratory Adverse Events
Respiratory depression indicators will be measured every 6 hours. 1\) The presence of any of the following will be considered respiratory depression: 1. Respiratory rate \<8 or oxygen saturation \<90% for longer than 5 minutes 2. Increased oxygen requirement by ≥ 2 L O2 for 15 min 3. naloxone use. Patients who are receiving 4. supplemental oxygen
Time frame: 18 months
Estimate Reduction in Opioid Use
To estimate reduction in opioid use (Morphine Milligram Equivalents, MME) in the acute postoperative period as a mechanistic indicator for decrease in opioid usage at 3 months. Postoperative 5-day opioid requirements assessed by total MME (5 days duration or length of hospitalization, whichever is earlier) will be compared between methadone and placebo groups
Time frame: 90 days
Development of and effective study design
To estimate key design parameters (variability and effect size) of a large clinical trial which will evaluate the reduction in chronic opioid use at 3 months post-surgery. Focusing on estimating parameters that will be needed to appropriately calculate the sample size for a larger trial.
Time frame: 24 months
Plan to share: Yes — The investigator plans to share information by presenting abstract/journal materials pending results.
Supporting information: Study protocol, Analytic code
Time frame: De-identified data will be available post-analysis in abstract/journal articles.
Started Nov 2025 (actual). Primary completion is estimated for Oct 2027, 23 months after the start.
Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 23 months is above that.
Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methadone